A chaotropic agent disrupts weaker antigen-antibody interactions while leaving stronger interactions more resistant. In an avidity assay, antibody binding is measured before and after this treatment, and the remaining signal indicates the relative strength of the multivalent interaction. A larger retained signal therefore reflects greater resistance to disruption, rather than simply more antibody being present.
B-cell responses generally mature through affinity selection, favoring antibodies that bind their targets more effectively. As this process proceeds, the overall binding strength of the antibody population can increase, producing higher measured avidity. This makes avidity a useful indicator of response maturation and helps distinguish a recent response from one that has become established.
Affinity describes the strength of an individual antibody-binding interaction, whereas avidity reflects the combined effect of multiple binding sites and their interactions with an antigen. Consequently, avidity can capture the functional strength of a multivalent antibody-antigen interaction more broadly than a measurement focused on one binding event. This distinction matters when interpreting antibody quality.
A typical workflow compares antibody binding under two conditions: before and after exposure to a chaotropic agent. The treatment selectively disrupts weaker interactions, and the resulting binding signals are compared with the untreated signal. This paired design provides a relative avidity assessment while keeping the antibody-antigen system under direct comparison.
In infection research, avidity measurement can add timing-related information to serological testing. Because antibody avidity generally rises as responses mature, the result may help distinguish antibodies associated with a recent response from those reflecting an established immune response. It therefore complements antibody detection when infection history is an important part of interpretation.
Researchers can use avidity measurement to examine whether vaccination produces antibodies with stronger, more mature interactions and to assess the quality and durability of the resulting response. The assay can also support comparisons of immune responses after infection or vaccination. Its value lies in evaluating binding strength alongside the presence of antibodies, not merely antibody detection alone.